Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 470 matching drugs for PDE6H — including drugs targeting any of its 40 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
pentoxifylline PDE6H Direct yes 0
sunitinib CSF1R SSL via CSF1R yes 5
sunitinib KIT SSL via KIT yes 5
sunitinib PDGFRA SSL via PDGFRA yes 5
sunitinib PDGFRB SSL via PDGFRB yes 5
docetaxel, thalidomide ORM1 SSL via ORM1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KIT SSL via KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NTRK1 SSL via NTRK1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRA SSL via PDGFRA 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRB SSL via PDGFRB 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RET SSL via RET 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KIT SSL via KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) NTRK1 SSL via NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRA SSL via PDGFRA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRB SSL via PDGFRB 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RET SSL via RET 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BCR SSL via BCR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSF1R SSL via CSF1R 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KIT SSL via KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib NTRK1 SSL via NTRK1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PDGFRA SSL via PDGFRA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PDGFRB SSL via PDGFRB 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib RET SSL via RET 3
pembrolizumab, belzutifan, lenvatinib KIT SSL via KIT 3
pembrolizumab, belzutifan, lenvatinib PDGFRA SSL via PDGFRA 3
pembrolizumab, belzutifan, lenvatinib RET SSL via RET 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel RET SSL via RET 2
avapritinib KIT SSL via KIT yes 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment BCR SSL via BCR 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment KIT SSL via KIT 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PDGFRB SSL via PDGFRB 2
cabozantinib RET SSL via RET 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib RET SSL via RET 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib DDR1 SSL via DDR1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib NTRK1 SSL via NTRK1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PDGFRB SSL via PDGFRB 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib RET SSL via RET 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KIT SSL via KIT 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a PDGFRA SSL via PDGFRA 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a RET SSL via RET 2
lenvatinib, pembrolizumab KIT SSL via KIT 2
lenvatinib, pembrolizumab PDGFRA SSL via PDGFRA 2
lenvatinib, pembrolizumab RET SSL via RET 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KIT SSL via KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate PDGFRA SSL via PDGFRA 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate RET SSL via RET 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KIT SSL via KIT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PDGFRA SSL via PDGFRA 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a RET SSL via RET 2
nintedanib PDGFRA SSL via PDGFRA yes 2
nintedanib PDGFRB SSL via PDGFRB yes 2
nintedanib, pembrolizumab PDGFRA SSL via PDGFRA 2
nintedanib, pembrolizumab PDGFRB SSL via PDGFRB 2
pazopanib KIT SSL via KIT yes 2
pazopanib PDGFRA SSL via PDGFRA yes 2
pazopanib PDGFRB SSL via PDGFRB yes 2
pembrolizumab, lenvatinib KIT SSL via KIT 2
pembrolizumab, lenvatinib PDGFRA SSL via PDGFRA 2
pembrolizumab, lenvatinib RET SSL via RET 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KIT SSL via KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu PDGFRA SSL via PDGFRA 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu RET SSL via RET 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KIT SSL via KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin PDGFRA SSL via PDGFRA 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin RET SSL via RET 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery RET SSL via RET 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib KIT SSL via KIT yes 2
regorafenib NTRK1 SSL via NTRK1 2
regorafenib PDGFRA SSL via PDGFRA yes 2
regorafenib PDGFRB SSL via PDGFRB yes 2
regorafenib RET SSL via RET yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
regorafenib, laboratory biomarker analysis KIT SSL via KIT 2
regorafenib, laboratory biomarker analysis NTRK1 SSL via NTRK1 2
regorafenib, laboratory biomarker analysis PDGFRA SSL via PDGFRA 2
regorafenib, laboratory biomarker analysis PDGFRB SSL via PDGFRB 2
regorafenib, laboratory biomarker analysis RET SSL via RET 2
sorafenib, administered orally, ct/mri KIT SSL via KIT 2
sorafenib, administered orally, ct/mri PDGFRB SSL via PDGFRB 2
sorafenib, administered orally, ct/mri RET SSL via RET 2
thalidomide ORM1 SSL via ORM1 2
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib BCR SSL via BCR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib KIT SSL via KIT 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PDGFRB SSL via PDGFRB 1
atezolizumab, cabozantinib RET SSL via RET 1
atezolizumab, tivozanib KIT SSL via KIT 1
atezolizumab, tivozanib PDGFRA SSL via PDGFRA 1
atezolizumab, tivozanib PDGFRB SSL via PDGFRB 1
avapritinib, midazolam KIT SSL via KIT 1
bevacizumab, dasatinib, placebo ABL1 SSL via ABL1 1
bevacizumab, dasatinib, placebo BCR SSL via BCR 1
bevacizumab, dasatinib, placebo KIT SSL via KIT 1
bevacizumab, dasatinib, placebo PDGFRB SSL via PDGFRB 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.